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Background: Neural tube defects (NTDs) are 
serious birth defects arising from abnormalities in 
neural tube development during early 
embryogenesis. Research shows that taking folic 
acid prior to and throughout the first 12 weeks of 
pregnancy will significantly decrease the 
occurrence of NTDs. The prevalence of NTDs in 
Malta is 10.0/10,000 births, yet this rate can be 
brought down to 5.0-6.0/10,000 births with 
preconception folic acid. This study aims to 
investigate the maternal intake of preconception 
folic acid in Malta. 
Methods: The National Obstetric Information 
System (NOIS) collects detailed demographic, 
pregnancy, delivery and infant outcome data on all 
births in Malta. One of the variables recorded at the 
first antenatal visit is whether the mother took folic 
acid prior to pregnancy. NOIS data for 2015 was 



























Results: 4385 women delivered a baby in 
2015, of these 1125 (25.7%) reported taking folic 
acid before pregnancy. Both univariate and 
multivariate logistic regression showed that 
maternal age, parity, education, nationality, locality 
of residence, marital status, planned pregnancy and 
use of artificial reproductive technology were all 
significantly associated with taking preconception 
folic acid (p<0.001). 
Conclusion: Although preconception folic 
acid supplementation has been advised since the 
early 1990s, in Malta only a quarter of mothers are 
taking this before pregnancy. This low compliance 
is also documented in other countries. Several 
maternal factors have been found to be associated 
with better intake of preconception folic acid. 
Effective methods of increasing maternal 
preconception intake of folic acid are necessary to 
decrease the rate of NTDs in Malta. 
 
Key words 




Neural tube defects, namely anencephaly and 
spina bifida, occur at an overall rate of 9.83/10,000 
births in Europe with a livebirth rate of 2.61/10,000 
livebirths.1 These are severe, debilitating birth 
defects responsible for causing significant 
morbidity and mortality. Folic acid is known to be 
important for the normal development of the neural 
tube in early embryogenesis and its effects have 
been widely investigated. In 1991, a landmark 
multicentre double blind randomised control study 
conducted by the Medical Research Council 
conclusively showed that taking folic acid in the 
peri-conceptional period (i.e. from one month 
before conception through to 12 weeks after 
conception) effectively prevents the occurrence of 
neural tube defects by up to 50-70%.2 It has since 
been documented in several other studies that taking 
folic acid at the correct time can significantly 
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decrease the occurrence of neural tube defects.3 
This knowledge prompted countries 
worldwide including the UK and USA to issue 
recommendations as early as 1992 for all women of 
childbearing age to take regular folic acid 
supplements.4,5 In spite of these recommendations 
and accompanying health promotion initiatives, it 
was found that whilst women’s knowledge and 
awareness of the benefits of folic acid had increased 
significantly, its use in the peri-conceptional period 
had not increased to the desired levels and many 
mothers were still not taking preconception folic 
acid.  More importantly, the occurrence of neural 
tube defects had not decreased significantly.6  
Within this scenario, a number of countries 
introduced mandatory food fortification of flour to 
ensure that women were taking the required 
amounts of folic acid before and during the early 
weeks of conception. These initiatives have 
translated into a significant decrease in neural tube 
defects in those countries having implemented 
mandatory food fortification with folic acid, whilst 
these benefits have not been seen in countries 
without mandatory fortification.7 
Europe has not introduced mandatory food 
fortification with folic acid for several reasons 
including reasons of protecting personal choice and 
fear of possible negative health effects associated 
with widespread population intake of folic acid, 
although the latter have not been confirmed.8 
Europe, including Malta, therefore currently relies 
on initiatives such as recommendations, health 
promotion campaigns and women’s voluntary 
supplementation with folic acid preconceptionally. 
The total prevalence rate of NTDs in Malta is 
11.14/10,000 births with a livebirth rate of 
9.0/10,000,9 yet it has been documented that the rate 
of non-preventable NTDs can be brought down to 
5-6/10,000 births when folic acid is taken correctly 
in the preconception period.10 
Health professionals in Malta generally follow 
UK NICE guidelines in their practice. These 
guidelines recommend that women of childbearing 
age take ‘400 micrograms daily before pregnancy 
and throughout the first 12 weeks, even if they are 
already eating foods fortified with folic acid or rich 
in folate’.11  
This study aims to investigate the current 
maternal intake of preconception folic acid in Malta 
and the factors associated with an increased 
probability of the mother taking preconception folic acid. 
Methods 
Detailed medical birth data on all deliveries 
and births on the Maltese Islands are collected on a 
routine basis by the National Obstetric Information 
System (NOIS) of the Directorate for Health 
Information and Research (DHIR). This is the 
official medical births data source of Malta. 
Detailed demographic, pregnancy, delivery and 
outcome data for all births of 22 weeks gestation 
and over is collected at the obstetrics units from the 
hospital medical records and forwarded to the 
DHIR where the data is checked, validated and 
entered into the NOIS database. 
At their first antenatal clinic visit at hospital, 
women are routinely asked whether they have been 
taking folic acid supplements and whether they 
started them before pregnancy. For the period 
between 1st January and 31st December 2015 this 
data was inputted into the NOIS database.  
Anonymous data on mothers’ reported 
preconception folic acid intake together with 
maternal age, parity, marital status, education, 
nationality, locality of residence, planned pregnancy 
and use of assisted reproductive technology (ART) 
for the year 2015 was extracted from the NOIS 
database and used for this retrospective registry 
based study. Maternal nationalities were grouped 
into 5 categories reflecting the maternal geographic 
region of origin: i) Malta, ii) countries which joined 
the EU pre-2004 and EFTA countries, iii) other 
European countries, iv) Africa or Middle East and 
v) all others. Maternal locality of residence was 
categorised into 6 districts according to the system 
of Local Administrative Units (LAUs) created by 
EUROSTAT which is compatible with the 
Nomenclature of Territorial Units for Statistics 
(NUTS).12 
Excel and SPSS were employed to analyse the 
data using chi-square and multivariate logistic 
regression analysis.  
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Table 1: Characteristics of mothers and their reported preconception folic acid intake 


















% (95% CI) of 
mothers taking 










4385 1125 25.7  (24.4-27.0)    
Age 
<25 640 45   7.0  ( 5.5 -09.4) 
92.6 2 p<0.001 25-35 3126 908 29.0  (27.5-30.7) 
>35 619 172 27.8  (24.3-31.5) 
Nationality 
Maltese 3544 998 28.2  (26.7-29.7) 
59.5 4 p<0.001 
EU pre 2004 
& EFTA 217 45 20.7  (25.7-26.9) 
Other 
European 242 48 19.8  (15.1-25.5) 
Africa & 
Middle East  281 12 4.3   ( 2.3 - 7.5) 




    
37.2 5 p<0.001 
North 789 216 27.4  (24.3-30.7) 
Western 548 196 35.8  (31.8-40.0) 
N.Harbour 1332 307 23.0  (20.8-25.4) 
S.Harbour 719 132 18.4  (15.6-21.4) 
South East 705 210 29.8  (26.6-33.3) 




Tertiary 1481 556 37.5  (35.1-40.1) 
93.6 2 p<0.001 
Vocational/ 
non-tertiary 1047 279 26.7  (24.0-29.5) 
Secondary 1629 281 17.2  (15.5-19.2) 
Marital 
Status 
Married 3009 977 32.5  (30.8-34.2) 
150.8 2 p<0.001 
Single 1197 120 10.0  ( 8.4 -11.9) 
Separated/ 
divorced 179 28 15.6  (10.8-22.0) 
Parity 
Nulliparous 2223 703 31.6  (29.7-33.6) 
50.0 1 p<0.001 
Multiparous 2162 422 19.5  (17.9-21.3) 
Planned 
Pregnancy* 
Yes 2884       1074 37.2  (35.5-39.0) 
325.5 1 p<0.001 
No 1216 40 3.3  ( 2.4 – 4.5) 
ART 
Yes 97 63 64.9  (54.5-74.2) 
36.4 1 p<0.001 
No 4288       1062 24.8  (23.5-26.1) 
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Table 2: Odds Ratios for univariate and multivariate logistic regression for characteristics of mothers and 
associated preconception folic acid intake 
 
    UNIVARIATE OR (95% CI) ADJUSTED OR (95% CI) 
Characteristic Categories OR Lower CI Upper CI p-value Adj OR Lower CI Upper CI p-value 
Age  
25-35yrs 1.00     p<0.001 1.00     p<0.001 
 <25yr 0.18 0.14 0.25 0.44 0.31 0.63 
 >35yr 0.94 0.78 1.14 1.24 0.98 1.56 
Nationality  
Maltese 1.00     p<0.001 1.00     p<0.001 
EU pre2004 
& EFTA 0.67 0.48 0.93 0.78 0.53 1.15 
Other 
European 0.63 0.46 0.87 0.54 0.38 0.78 
Africa & 
Middle East 0.11 0.06 0.20 0.10 0.05 0.22 




North 1.00     p<0.001 1.00     p<0.001 
Western 1.48 1.17 1.87 1.26 0.96 1.65 
N.Harbour 0.79 0.65 0.97 0.99 0.79 1.26 
S.Harbour 0.60 0.47 0.76 0.80 0.60 1.06 
South East 1.13 0.90 1.41 1.18 0.91 1.54 




Tertiary 1.00     p<0.001 1.00     p<0.001 
Vocational 
/ non-
tertiary 0.60 0.51 0.72 0.77 0.63 0.94 
Secondary 0.35 0.29 0.41 0.62 0.51 0.75 
Marital 
Status  
Married 1.00     p<0.001 1.00     p<0.001 
Single 0.23 0.19 0.28 0.46 0.36 0.59 
Separated 
/divorced 0.39 0.26 0.58 0.51 0.32 0.81 
Parity  
Nulliparous 1.00     p<0.001 1.00     p<0.001 
Multiparous 0.52 0.46 0.60 0.50 0.43 0.59 
Planned 
Pregnancy  
No  1.00     p<0.001 1.00     p<0.001 
Yes  17.45 12.62 24.12 11.87 8.52 16.55 
ART  
No  1.00     p<0.001 1.00     p<0.001 
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A total of 4385 women delivered a baby of 22 
weeks gestation or over in 2015, of these 1125 
(25.7%) women reported having taken folic acid 
before pregnancy. 
Table 1 presents a comparison of mothers 
having reported taking preconception folic acid and 
others not having taken preconception folic acid 
according to various maternal characteristics with 
the level of significance. Maternal age, parity, 
education, nationality, locality of residence, marital 
status, pregnancy planning and use of ART were all 
found to be very significantly associated (p<0.001) 
with use of preconception folic acid 
supplementation. 
Multivariate logistic regression showed that 
all parameters tested were independently associated 
with the likelihood of having or not having taken 
preconception folic acid (Table 2). Results showed 
that women having had a planned pregnancy or 
having undergone ART were the most likely to take 
preconception folic acid with adjusted odds ratios of 
11.87 (95% CI 8.52-16.55) and 2.67 (95% CI 1.67-
4.29) respectively (Table 2).  
Low educational level, multiparity, unmarried 
mothers, mothers younger than 25 years and foreign 
mothers (i.e. Non-Maltese and non-EU pre-
2004/EFTA nationality) were independently, 
significantly associated with a lower likelihood of 
taking preconceptional folic acid.  
Analysis of maternal locality of residence by 
region was also significantly associated with taking 
supplemental folic acid preconceptionally, with 
Gozitan women reporting taking significantly less 
folic acid before pregnancy than women residing in 
other areas.  
 
Discussion 
In spite of the long-term knowledge of the 
benefits of preconception folic acid, only a quarter 
(25.7%) of the mothers delivering in Malta reported 
having taken folic acid before pregnancy. This rate 
is too low to avoid all potentially preventable 
NTDs. Similar undesirably low rates have been 
documented in several other European countries.13 
In this study, higher maternal educational 
level was found to be significantly associated with 
increased preconception folic acid intake. Similar 
findings have been documented in other studies. A 
study from the Netherlands in 2008 found that 
while 31% of women with low educational level 
had taken peri-conceptional folic acid supplements,  
63% of women with a high educational level had 
taken preconception supplementation.14 A more 
recent Italian study of over 2189 women by Nilsen 
at al. (2016) reported that 9.4% of mothers with low 
educational level took preconception folic acid 
compared to 31.1% of mothers with a tertiary 
education level.15  
Similar to other studies, young women were 
found to be the least likely to take folic acid 
supplementation preconceptionally, with only 7.0% 
of mothers in Malta aged less than 25 years taking 
preconception folic acid.16 Furthermore, nulliparous 
women were found to be more likely to take 
preconception folic acid than multiparous women as 
also found in other studies.17 In our study, mothers 
of African or European non-EU origin were 
associated with the lowest rates of preconception 
folic acid intake. This highlights the possibility of 
existent health inequalities and issues with health 
promotion messages and recommendations reaching 
foreign mothers and mothers of minority ethnic 
groups. In the UK, a study of nearly half a million 
pregnant women by Bestwick et al. (2014) also 
describes a troubling situation where non-Caucasian 
women were far less likely to take folic acid before 
pregnancy, a situation, they conclude, which is 
leading to health inequalities.18 
Understanding the characteristics of women 
least likely to take folic acid preconceptionally can 
inform policy to better target initiatives aimed at 
increasing women’s preconception folic acid intake. 
Any initiatives undertaken must ensure that they 
effectively reach those categories of women 
identified as being less likely to be taking folic acid 
in the recommended period, avoiding inequalities 
between women of different socioeconomic 
status.19 
While Health Promotion campaigns are often 
considered the first line intervention to affect a 
change in behaviour, research has shown that non-
targeted campaigns have been of limited success in 
increasing women’s intake of folic acid. A 
systematic review investigating the rates of 
preconception folic acid uptake in various countries 
before and after health promotion campaigns shows 
that the rate of uptake following intervention varies 
and increased on average from 14 to 23%.20  These 
disappointing results indicate that health promotion 
campaigns have not been successful in satisfactorily 
changing women’s behaviours.14,21 It has been 
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suggested that alternative interventions including 
health-care based interventions such as making folic 
acid supplements easily available may be found 
more effective in the longer term than using mass 
media or printed resources in isolation.19 
Pregnancy planning and undertaking assisted 
reproduction were found to be the characteristics 
most significantly associated with increased 
maternal intake of folic acid. These associations 
have also been described elsewhere and indicate 
that an effective way of increasing peri-
conceptional folic acid intake might be to improve 
family planning by providing appropriate clinics.15  
Women’s knowledge and intake of folic acid 
supplements is influenced significantly by health 
care professionals’ advice, namely general 
practitioners, obstetricians, paediatricians and 
pharmacists.22 General practitioners have an 
important role in increasing awareness and 
improving preconceptional folic acid intake. It is 
important that they are aware of this and give 
appropriate advice to all women of childbearing age 
even when they are attending clinics for other 
reasons. Unfortunately, it has been documented that 
a number of family doctors are themselves not fully 
aware of the benefits and correct timing and dosage 
of peri-conceptional folic acid intake.23 Although 
obstetricians are fully aware and do provide folic 
acid supplementation advice, women generally 
present at the obstetricians’ clinics following 
conception, at a time too late for prevention of 
potentially avoidable NTDs. Post-natal clinics could 
also provide a venue for educating and informing 
women of the benefits of folic acid for future 
pregnancies. Other sources of information on the 
importance of folic acid include the media, family 
and friends. Our data did not have data on maternal 
sources of folic acid knowledge and this could not 
be studied for the local scenario.  
Preconception clinics have been implemented 
in several countries with the aim of improving 
pregnancy and infant outcomes.24 The Italian study 
by Nilsen et al. (2016), reported that the adjusted 
prevalence ratio of taking preconception folic acid 
for women intending to get pregnant who attended a 
health visit prior to conception was 7.90 (95% CI 
4.62-13.5), compared to 2.87 (95% CI 1.72-4.79) 
for women with pregnancy intention but not having 
attended a preconception health visit.15 Women 
suffering from diseases needing pregnancy planning 
have also been found to be significantly more likely 
to take preconception folic acid with an adjusted 
odds ratio of 1.7 (95% CI 1.2-2.5).16  Preconception 
clinics are ideal venues that may educate and 
encourage women to take preconception folic acid 
supplements, however, such clinics are not 
available in Malta.  
Limitations of this study include the fact that 
folic acid uptake relied on maternal reporting and 
the actual uptake of folic acid may be lower than 
that reported due to maternal non-compliance and 
their reluctance to report this. Additionally, the 
doses and exact timing of folic acid 




In the absence of mandatory food fortification, 
countries must be innovative and pro-active in 
undertaking initiatives to improve women’s folic 
acid uptake with the aim of avoiding potentially 
preventable devastating birth defects as are neural 
tube defects. This is an area which undisputedly 
offers great public health potential. It is important to 
ensure that any initiatives undertaken reach all 
maternal categories including the more vulnerable 
women. Having local research determining 
women's views of the barriers and enablers to the 
uptake of preconception care and peri-conceptional 
folate supplementation may also go a long way in 
directing effective policy making in this area. 
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